Search

Issue
Title
Authors
Preclinical studies of cytotoxicity and cytostatic activity of five new imidazotriazine derivatives in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures
Al-Humairi A.H., Buldakov M.A., Novochadov V.V., Cherdyntseva N.V., Udut V.V.
Role of repeat biopsies of metastatic and recurrent lesions for the study of tumor heterogeneity in luminal breast cancer: Retrospective and prospective analyses
Gluzman M.I., Chistyakova E.A., Raskin G.A., Orlova R.V.
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D., Borisov D.A., Makarova M.V.
Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
A clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report
Medvedev S.V., Vlasova M.Y., Bolotina L.V., Kaprin A.D., Khmelevskiy E.V., Zikiryakhodzhaev A.D., Khakimova S.G., Khakimova G.G., Bychkova N.M., Zaitseva N.A., Abushova E.R., Guseva S.D., Maslov E.D.
New therapies for hormone-positive HER2-negative metastatic breast cancer with AKT signaling alterations: the Expert Panel Decision
Editorial B.
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)
Uvarova K.G.
Avastin in clinical chemotherapy of malignant tumors
Gorbunova V.A.
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
Sokolova T.N., Solov'eva T.I., Aleksakhina S.N., Janus G.A., Goryainova A., Gluzman M.I., Orlova R.V., Stukan A.I., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Sultanbaev A.V., Vorobeva E.N., Mikhaevich L.M., Pyliv V.N., Lysenko A.N., Khachmamuk Z.K., Kozlov A.E., Bakharev S.Y., Parsyan S.G., Rossokha E.I., Osidze L.D., Shumskaya I.S., Agaeva A.V., Kasmynina T.A., Klimenko V.V., Akhmetgareeva K.T., Vakhitova A.A., Chakhkieva M.D., Dmitriev V.N., Bakshun Y.I., Vasilyev A.E., Gasimly D.D., Kravchenko N.A., Maksimov D.A., Nesterova A.I., Sharvashidze I.O., Gadzaova C.H., Rakhmankulova G.G., Khamgokov Z.M., Amirkhanova I.K., Bembeeva L.V., Vladimirov V.I., Petrenko O. ., Ruskova N.G., Serikova E.L., Subbotina K.S., Tkachenko S.A., Chang V.L., Erdniev S.P., Barbara V.S., Vasilevskaya A.V., Mikheeva Y.V., Popova N.O., Startseva E.P., Fateeva A.V., Yukalchuk D.Y., Grechkina A.A., Musaeva K.S., Odintsova S.V., Stel'makh A.S., Khabibulaeva P.I., Khlobystina A.G., Shvaiko K.A., Basova E.A., Bogomolova I.A., Bolieva M.B., Goldberg V.E., Kibisheva M.V., Menshikov K.V., Ryazanov D.V., Stepanova M.L., Udalova Y.A., Shkradyuk A.V., Chapko Y.S., Shchukina A.A., Khabriev I.M., Kirtbaya D.V., Degtyarev A.M., Epkhiev A.A., Tyugina Y.A., Murachuev M.A., Togo A.V., Ievleva A.G., Imyanitov E.N.
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review
Sultanbaev A.V., Kolyadina I.V., Gilyazova I.R., Nasretdinov A.F., Musin S.I., Sultanbaeva N.I., Menshikov K.V.
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Frank G.A., Komov D.V., Karseladze A.I., Bastiaannet E., Dekker-Ensink N.G.
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Long-term aesthetic outcomes of reconstructive surgeries with endoprosthetics for breast cancer: A review
Khomidi U.K., Vlasova M.Y., Saribekyan E.K., Zikiryakhodzhaev A.D., Khakimova S.G., Khakimova G.G., Kodzoeva D.B.
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
Editorial B.
Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case
Radyukova I.M., Rats N.M.
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
Gordeeva O.O., Kolyadina I.V., Zhukova L.G., Gan'shina I.P., Komov D.V., Meshcheriakov A.A.
Prognostic value of p53 expression in patients with stage I breast cancer
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Liefers G.J., Dekker-Ensink N.G., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
Karabina E.V., Zhukova L.G.
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer
Kolyadina I.V., Danzanova T.Y., Khokhlova S.V., Trofimova O.P., Kovaleva E.V., Rodionov V.V., Poddubnaya I.V.
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
Kolyadina I.V., Poddubnaya I.V.
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan
Berdimyradova M.B., Khadjiev S.M., Khommadova D.N., Polatova G.O., Kakajanova A.O., Batyrov C.B., Penayev D.N., Agayeva B.G., Annaberdiyeva G.A.
Influence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study
Duadze I.S., Kaprin A.D., Zikiryakhodzhaev A.D., Reshetov I.V., Usov F.N., Rasskazova E.A., Sukhotko A.S., Starkova M.V., Bagdasarova D.V., Dzhabrailova D.S., Khakimova S.G.
Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer
Pavlikova O.A., Kolyadina I.V., Komov D.V., Vishnevskaya Y.V., Poddubnaya I.V.
Rare morphological forms of breast cancer: features of surgical approach
Vysotskaya I.V., Letyagin V.P., Kolyadina I.V., Martynova G.V.
Squamous cell breast cancer: description of a rare clinical case
Zikiryakhodjaev A.D., Khakimova S.G., Rasskazova E.A., Saribekian E.K., Omarova D.F., Surkova V.S., Khakimova G.G.
Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade
Lichinitser M.R., Semenov N.N.
Experience in the treatment of radioinduced angiosarcoma of the breast in a patient with primary multiple lesions of the breast and bladder. Case report
Semenov E.V., Gasymly D.D., Zyuzyukina A.V., Zukov R.A.
The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer
Vashenko L.N., Daschkova I.R., Bakulina S.M., Andreyko E.A.
Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study
Golubenko E.O., Savelyeva M.I., Poddubnaya I.V., Korennaya V.V.
Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study
Sultanbaev A.V., Menshikov K.V., Musin S.I., Nasretdinov A.F., Fatikhova A.A., Izmailov A.A., Lipatov O.N., Ayupov R.T., Sultanbaeva N.I., Menshikova I.A., Serebrennikov G.A.
Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy
Benefits and limitations of breastfeeding for mothers with malignant tumors
Ladodo O.B., Iurova M.V., Khokhlova S.V., Rodionov V.V., Sheshko E.L., Zubkov V.V., Makieva M.I., Chutkova D.A., Akhapkina E.S., Degtyarev D.N.
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V.I., Bloshchinenko A.A., Abolmasov A.E., Vilensky A.A., Laskov M.S.
Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
Zabotina T.N., Chertkova A.I., Borunova A.A., Kushlinskii N.E., Gershtein E.S., Zakharova E.N., Shoua E.K., Tsiklauri V.T., Samoylenko I.V., Khoroshilov M.V., Kadagidze Z.G.
PARP inhibitors in female reproductive system cancers
Pokataev I.A., Tyulyandin S.A.
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Chumakov P.M., Ilinskaya G.V., Bokhian V.Y., Sopova M.I.
Immunological predictors of the therapeutic efficacy of atezolizumab in combination with nab-paclitaxel in metastatic triple-negative breast cancer: A pilot multicenter retrospective associative study
Kalinchuk A.Y., Popova N.O., Gofman A.A., Usoltseva I.S., Perelmuter V.M., Tashireva L.A.
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L.G., Bolotina L.V., Dvornichenko V.V., Fadeeva N.V., Ganshina I.P., Grechukhina K.S., Hasanova A.I., Kislov N.V., Kudryavtsev I.Y., Manikhas A.G., Musaeva N.E., Nizhegorodtseva A.A., Sadikova O.E., Sakaeva D.D., Snegovoy A.V., Stroyakovskiy D.L., Tjulandin S.A., Trishkina E.A., Vladimirova L.I., Volkov N.M., Kostalanova Y.V.
The effect of hormonal contraception on the risk of breast cancer: A review
Iurova M.V., Mezhevitinova E.A., Yakushevskaya O.V., Rodionov V.V., Prilepskaya V.N.
Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: a regional analysis
Valiachmetova C.K., Siraev E.R., Izmailov A.A.
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
Sokolova T.N., Aleksakhina S.N., Yanus G.A., Sultanbaev A.V., Menshikov K.V., Lysenko A.N., Zukov R.A., Zyuzyukina A.V., Murunova Y.N., Rossokha E.I., Bakharev S.Y., Basova E.A., Kasmynina T.A., Shumskaya I.S., Bakshun Y.I., Musaeva K.S., Khasanova A.I., Dmitriev V.N., Bolieva M.B., Gadzaova C.H., Petrenko O.L., Maksimov D.A., Vladimirov V.I., Goldberg V.E., Popova N.O., Kibisheva M.V., Khamgokov Z.M., Vasilyev A.E., Iyevleva A.G., Imyanitov E.N.
The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
Tabakov D.V., Zabotina T.N., Chanturia N.V., Zakharova E.N., Vorotnikov I.K., Selchuk V.Y., Sokolovskiy V.V., Petrovsky A.V.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case
Kolyadina I.V., Ganshina I.P., Zhukova L.G., Abdullaev A.G., Andreeva Y.Y., Danzanova T.Y., Sinyukova G.T., Komov D.V., Kozlov N.A., Filonenko D.A., Gordeeva O.O., Lubennikova E.V.
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Radiation-induced lung injury in breast cancer patients after breast conservation therapy
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom
Zhukova L.G., Abramov M.E., Vakhabova Y.V., Lud A.N., Obukhov A.A., Lichinitser M.R.
Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii
Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy?
Ptushkin V.V.
Aromazin: printsip deystviya
Imyanitov E.N.
Farmorubitsin v klinicheskoy praktike
Gorbunova V.A.
Analiz rezul'tatov vnedreniya Regional'noy rossiyskoy programmy lecheniya pervichno-generalizovannogo i metastaticheskogo raka molochnoy zhelezy v Voronezhskom oblastnom klinicheskom onkologicheskom dispansere
Chevardov N.I., Tolstykh L.V., Puzakov K.G., Potapov Y.N.
The role of ESR1 gene mutation in therapy selection for HR+/HER2- metastatic breast cancer: A review
Paichadze A.A., Chashnikova E.P., Golubeva S.A.
Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer
Ognerubov N.A., Barsukov S.V.
The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review
Grechukhina K.S., Kalugin M.V., Prosvirnov A.A., Sukhova M.V., Zhukova L.G.
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov D.A., Chulkova S.V., Shamilov F.A., Chanturia N.V., Zheltikov S.D., Tupitsyn N.N.
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports
Savelyeva M.I., Dudina I.A., Zaharenkova J.S., Ignatova A.K., Ryzhikova K.A., Sozaeva Z.A., Kudlay D.A., Perfileva O.M., Poddubnaya I.V.
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A.
Klinicheskiy sluchay effektivnogo lecheniya lapatinibom (Tayverb)i kapetsitabinom (Kseloda) bol'noy disseminirovannym rakom molochnoy zhelezy s giperekspressiey ErbB2 (Her-2/neu) s metastaticheskim porazheniem veshchestva i obolochek golovnogo mozga
Naskhletashvili D.R., Chmutin G.E.
Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)
Zhukova L.G.
Femara (letrozol) v sovremennoy terapii raka molochnoy zhelezy
Perevodchikova N.I.
8 let nadezhdy: novye dannye issledovaniya ATAS
Primenenie Zomety na fone endokrinnoy terapii Femaroy u bol'nykh rakom molochnoy zhelezy s metastazami v kosti
Konstantinova M.M., Ovchinnikova L.K., Lomakin N.N., Galleev M.G., Neretina E.S., Mukhamedshina G.Z., Mukhametgaleeva F.K.
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)
Shisterova O.A., Golik E.P.
Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy
Makarenko N.P.
Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Kletsel' A.E., Arzumanov A.S., Ivanova O.A., Semiglazov V.V.
Mammography followed by ultrasonography compared to mammography alone for breast cancer screening in women at average risk of breast cancer (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
Editorial B.
Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report
Grechukhina K.S., Vorontsova K.A., Filonenko D.A., Tyutyunnik P.S., Shchadrova V.V., Zhukova L.G.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Bone mineral density in patient with breast cancer
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A.
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V.F., Semiglazov V.V., Zhil'tsova E.K.
Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa
Novik A.A., Ionova T.I., Kalyadina S.A.
Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy
Stenina M.B.
Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode
Arslanov K.S., Tkachenko G.A.
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
Samoylenko V.M., Gorbunova V.A., Koshelev M.N., Yurashko K.V.
Faktory prognoza pri rake molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Semiglazov V.V., Arzumanov A.S., Kletsel' A.E.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Ognerubov N.A.
Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research
Kolomejtseva A.A., Bokova S.E.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Ganshina I.P., Khokhlova S.V., Kоmetova V.V., Rodionov V.V.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
Board E.
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Ganshina I.P., Ivanova K.A., Lubennikova E.V., Arkhipov A.V., Zhukova L.G.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K.S., Zhukova L.G.
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
Gorbunova V.A., Kolyadina I.V., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Filonenko D.V., Zhilyaeva L.A., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Suslova I.R., Romanchuk O.V., Kozlov D.V., Rzaev A.S., Marfutov V.V., Andreiashkina I.I., Vladimirova L.I., Mitashok I.S., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Morozov D.A., Prokof'eva E.P., Kramskaia L.V., Karandeeva T.V., Evstigneeva I.V., Ovchinnikova E.G., Klement'eva T.P., Khrupalo O.V., Tiuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov D.D., Gaisina E.A., Levchenko N.V., Chubenko V.A., Povyshev A.I., Iudina I.V., Vorotilina L.V., Andreeva T.V., Tumanian G.S., Koziakov A.E., Gil'mutdinova L.A., Osipov M.A., Shatokhina A.S., Vazhenina A.A., Chichkanova A.S., Vladimirov V.I., Ivanov A.N., Belokhvostova A.S., Cherniakova E.M., Tul'china E.A., Maklashova S.A., Shkodenko O.N., Kostalanova I.V., Tarasova A.V., Kuz'mina E.S.
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
Pavlikova O.A., Poddubnaya I.V., Kolyadina I.V., Abdullaev A.G., Komov D.V., Danzanova T.Y., Sinyukova G.T., Kozlov N.A., Ganshina I.P., Zhukova L.G., Aliyeva G.S., Kerimov R.A., Gordeeva O.O.
1 - 100 of 174 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"